Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer

Stathopoulos, George P.; Stathopoulos, J.; Dimitroulis, J.

doi:10.3892/ol.2012.836

Cited by 7 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A macromolecular formulation of cisplatin, termed lipoplatin, that appears to selectively accumulate in the tumor environment [3] is also progressing through clinical trials and could lead to more selective treatments with reduced side-effects [4]. Many other types of macromolecular systems are also under development [5].…”

Section: Page 6 Of 100mentioning

confidence: 99%

The development of RAPTA compounds for the treatment of tumors

Murray

Babak

Hartinger

et al. 2016

Coordination Chemistry Reviews

403

348

View full text Add to dashboard Cite

Section: Page 6 Of 100mentioning

confidence: 99%

The development of RAPTA compounds for the treatment of tumors

Murray

Babak

Hartinger

et al. 2016

Coordination Chemistry Reviews

403

348

View full text Add to dashboard Cite

“…As this liposomal formulation is less toxic, preclinical and clinical studies made on NSCLC have shown that a 3-6 times higher dose than the standard dose of cisplatin resulted to a better anticancer effect with lower toxicity [24,25]. In our studies, no toxicity was observed with Lipoplatin ™ as measured by the mean survival time of the animals compared to controls, whatever the route of administration used.…”

Section: Discussionmentioning

confidence: 40%

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

et al. 2013

View full text Add to dashboard Cite

Treatment of glioblastoma with platinum compounds modestly improves progression-free survival and may cause toxic effects which prevent use at higher dose that would otherwise improve the antineoplastic effect. To reduce toxicity, we propose to encapsulate the platinum drug in a liposome. We have also tested three methods of drug administration (intra-venous, intra-arterial and intra-arterial combined with blood brain barrier disruption) to determine which one optimizes the tumor cell uptake, limits the toxicity and delivers the best concomitance effect with radiotherapy. Cisplatin, oxaliplatin, their respective liposomal formulations, Lipoplatin ™ and Lipoxal ™ , and carboplatin were assessed in F98 glioma, orthotopically implanted in Fischer rats. We found that the modest accumulation of drugs in tumor cells after intra-venous injection was significantly improved when the intra-arterial route was used and further increased after the transient opening of the blood brain barrier with mannitol. The liposomal formulations have largely reduced the toxicity and have allowed a better exploitation of the anti-cancer activity of platinum agent. Although the liposomes Lipoplatin ™ and Lipoxal ™ have shown a similar ability to CIHR Author ManuscriptCIHR Author Manuscript CIHR Author Manuscript that of carboplatin, to accumulate in brain tumors, the highest additive effect with radiotherapy was obtained with carboplatin. We conclude that the intra-arterial infusion of carboplatin or Lipoxal ™ in concomitance with radiation therapy leads to the best tumor control as measured by an increase of mean survival time in Fischer rats implanted with the F98 glioma with a benefit in survival time of 13.4 and 6.5 days respectively compared to intra-venous.

show abstract

“…One successful example is the liposomal formation (e. g. SPI‐77, [6] Lipoplatin, [7] LiPlaCis [8] ) of cisplatin within nano‐sized hydrophilic bilayers of phospholipids [8a,9] . Liposomal encapsulation enhances the circulation time of the drug, leading to increased drug accumulation at the tumor site through the enhanced permeability and retention (EPR) effect with a simultaneous reduction of adverse side effects [7a,8a,9] …”

Section: Introductionmentioning

confidence: 99%

In Vitro Anticancer Activity of Nanoformulated Mono‐ and Di‐nuclear Pt Compounds

Wang

Zhang

et al. 2021

Chemistry An Asian Journal

View full text Add to dashboard Cite

Nanoformulations of mononuclear Pt complexes cis-PtCl 2 (PPh 3 ) 2 (1), [Pt(PPh 3 ) 2 (LÀ Cys)] • H 2 O (3, LÀ Cys = L-cysteinate), trans-PtCl 2 (PPh 2 PhNMe 2 ) 2 (4; PPh 2 PhNMe 2 = 4-(dimethylamine)triphenylphosphine), trans-PtI 2 (PPh 2 PhNMe 2 ) 2 ( 5) and dinuclear Pt cluster Pt 2 (μ-S) 2 (PPh 3 ) 4 (2) have comparable cytotoxicity to cisplatin against murine melanoma cell line B16F10. Masking of these discrete molecular entities within the hydrophobic core of Pluronic® F-127 significantly boosted their solubility and stability, ensuring efficient cellular uptake, giving in vitro IC 50 values in the range of 0.87-11.23 μM. These results highlight the potential therapeutic value of Pt complexes featuring stable PtÀ P bonds in nanocomposite formulations with biocompatible amphiphilic polymers.

show abstract

Two consecutive days of treatment with liposomal cisplatin in non-small cell lung cancer

Cited by 7 publications

References 27 publications

The development of RAPTA compounds for the treatment of tumors

The development of RAPTA compounds for the treatment of tumors

Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain

In Vitro Anticancer Activity of Nanoformulated Mono‐ and Di‐nuclear Pt Compounds

Contact Info

Product

Resources

About